Di Grazia S.,University of Catania |
Succi G.,University of Catania |
Fraggetta F.,Cannizzaro Hospital |
Perrotta R.E.,University of Catania
Giornale di Chirurgia | Year: 2013
The giant cell tumor of tendon sheath (GCTTS) is the most common benign neoplasm in the hand after the ganglion cyst. Several hypotheses were formulated about the etiological factors of these tumors, but still there is not a common opinion on etiology, prognostic factors and recurrence rate. This article presents a review of literature of the last 15 years about GCTTS to assess the demographic, clinical and histological profile. We compared the information obtained from literature with our experience of 64 cases between 2000 and 2012. Our study showed similar results to those reported in literature, except for the recurrence rate: only 3 cases (4.7%) of 64 patients reported recurrence (versus about 15% on average in literature). Among the various possible factors that predispose to recurrence, it is necessary that the surgeon ensures complete excision of the tumor and removal of any residual satellite nodules. Although the marginal excision is the treatment of choice, it is often difficult to perform due to for the location and the strict adherence of the tumor to the tendon or neurovascular bundles. We used in all cases a magnifying loupe to help a careful research of satellite lesions and to respect surrounding structures. © 2013, CIC Edizioni Internazionali, Roma.
Improta G.,Laboratory of Clinical Research and Advanced Diagnostics |
Leone I.,Laboratory of Clinical Research and Advanced Diagnostics |
Donia M.,Copenhagen University |
Gieri S.,CNR Institute of Molecular Bioimaging and Physiology |
And 2 more authors.
OncoTargets and Therapy | Year: 2015
Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression upon ipilimumab and BRAF inhibitor. This review will focus on the clinical development and use of pembrolizumab in the clinical practice and in the management of advanced melanoma. © 2015 Improta et al.
Di Carlo I.,University of Catania |
Toro A.,University of Catania |
Pulvirenti E.,University of Catania |
Palermo F.,University of Catania |
And 2 more authors.
Surgical Oncology | Year: 2011
Background: The growing use of totally implantable venous access devices (TIVAD) has caused the simultaneous increase of various complications. Among these, one of the most encountered is the infection of the subcutaneous pocket in which the device is positioned, or the infection of TIVAD itself. The aim of this study is to evaluate the role of the antibiotic in the prevention of the infection of both the surgical site and the TIVAD within 30 days after the implant. Methods: The authors enrolled one hundred eight consecutive patients divided into two randomized arms each of 54 patients: group A (antibiotic), group B (no antibiotic). All patients were affected by solid tumors needing chemotherapy continuously. TIVADs were implanted surgically in cephalic vein. On the first, third, and seventh postoperative days, the following manifestations were considered as signs or symptoms of infection: pain, localized swelling, redness, and heat; white blood cell count was performed in the in-hospital laboratory. Body temperatures were checked twice a day for 7 days. A statistical analysis of the results was performed. Results: No sign of infection was recorded in both groups. Body temperatures and white blood cell counts remained within normal limits in both groups. One month after the procedure no patients recorded any sign of skin infection or body temperature increase. Conclusions: The study suggests that, following strict methods of pre- and postoperative care, TIVADs in patients with solid tumors may be surgically implanted without any antibiotic prophylaxis. © 2009 Elsevier Ltd. All rights reserved.
Vecchio G.M.,University of Catania |
Amico P.,University of Catania |
Grasso G.,Cannizzaro Hospital |
Vasquez E.,University of Catania |
And 2 more authors.
Pathology Research and Practice | Year: 2011
Although inflammatory pseudotumor (IPT) and inflammatory myofibroblastic tumor (IMT) may share a common morphology, they are distinct clinico-pathologic entities. Unfortunately, the terms IMT and IPT are still used interchangeably, especially when lesions occur in unusual sites, including breast. All the cases of IMT/IPT involving the breast have raised spontaneously without any apparent prior injury. We herein report the first case of a post-traumatic IPT of the breast parenchyma in a 22-year-old male. Histologically, the lesion was highly cellular and composed of spindle cells arranged in a predominant fascicular pattern. Notably, mono- or multi-nucleated large pleomorphic cells were observed. Inflammatory cells, especially plasma cells and lymphocytes, were closely admixed with the spindle cell proliferation. The overall picture was reminiscent of an " IMT with atypical features" , typically seen in lung, abdomen, pelvis, and retroperitoneum of children. Immunohistochemically, the spindle-shaped and large pleomorphic cells were immunoreactive to vimentin, α-smooth muscle actin, and desmin. No immunoreactivity was obtained with ALK-1 protein. The present case contributes to widening the morphological spectrum of IPT of the breast, emphasizing the possibility that a reactive lesion may contain large pleomorphic cells that may represent a potential diagnostic pitfall. Lastly, we suggest that the diagnosis of IMT of the breast should be rendered with caution when dealing with ALK-negative spindle cell lesions in adult patients, and alternative diagnoses, including IPT, should be seriously considered. © 2011 Elsevier GmbH.
Pepe P.,Urology Unit |
Garufi A.,Cannizzaro Hospital |
Priolo G.,Cannizzaro Hospital |
Candiano G.,Urology Unit |
And 4 more authors.
Anticancer Research | Year: 2013
Aim: Magnetic resonance imaging (MRI) accuracy in prostate cancer (PCa) diagnosis in men submitted to saturation prostate biopsy (SPBx) was evaluated. Materials and Methods: From June 2011 to December 2012, 78 patients (median 63 years) underwent repeat SPBx (median 28 cores). Multiparametric MRI using a 3 Tesla pelvic phased-array coil was performed before SPBx and lesions suspicious for PCa were submitted to additional targeted biopsies. Results: A T1c PCa was found in 32 (41%) cases. SPBx vs. MRI-suspicious targeted biopsy diagnosed 28 (87.5%) vs. 26 (81.2%) PCa missing four (12.5%) and six (18.8%) cancers localized in the anterior zone and in the lateral margin of the prostate, respectively; moreover, MRI diameter lesions correlated with PCa diagnosis and Gleason score (p<0.05). Conclusion: Multiparametric MRI improved SPBx accuracy in diagnosing PCa of the anterior zone; moreover, suspicious areas >10 mm resulted as highly predictive of cancer (about 70% of the cases).